Affordable Access

N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy.

Authors
  • Langdon, S P
  • Hickman, J A
  • Gescher, A
  • Stevens, M F
  • Chubb, D
  • Vickers, L M
Type
Published Article
Journal
European Journal of Cancer and Clinical Oncology
Publisher
Elsevier
Publication Date
Jun 01, 1985
Volume
21
Issue
6
Pages
745–752
Identifiers
PMID: 4018116
Source
Medline
License
Unknown

Abstract

N-Methylformamide (NMF) was found to be non-toxic to the bone marrow as reflected in the absence of leukopenia in mice, even when the marrow had been compromised by prior administration of cyclophosphamide. Thus recovery from the leukopenic nadir after 160 mg/kg of cyclophosphamide was unaffected by 200 mg/kg X 10 of NMF. This combination, given to animals bearing the M5076 sarcoma, proved to have an additive antitumour effect as measured by tumour growth delay and was superior to the antitumour effect of two doses of cyclophosphamide, a regime which prolonged the leukopenia. Furthermore, the hepatotoxicity of NMF was not augmented by the addition of cyclophosphamide. When hepatotoxicity was induced in BALB/c mice bearing the NMF-resistant ADJ/PC6A plasmacytoma, cyclophosphamide fully maintained its antitumour effect. The results show NMF to be a highly specific antiproliferative agent with potential for use in the therapy of patients with a compromised bone marrow and/or in combination chemotherapy.

Report this publication

Statistics

Seen <100 times